TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME WITH MESALAZINE AND/OR SACCHAROMYCES BOULARDII
نویسندگان
چکیده
منابع مشابه
Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
CONTEXT Irritable bowel syndrome (IBS) is a functional bowel disease characterized by abdominal pain and altered intestinal habits. The pathophysiology of IBS remains unclear. Recent studies have demonstrated that some IBS patients, especially in diarrhea-predominant IBS (IBS-D), display persistent signs of minor mucosal inflammation and a modified intestinal microflora. The mesalazine has know...
متن کاملTreatment of Diarrhea-Predominant Irritable Bowel Syndrome With Paroxetine
Sir: Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder. The disorder is characterized by chronic abdominal pain and altered bowel habits in the absence of any organic disorder. Treatment of IBS includes dietary modification, psychotherapies, and medications. Among medications, antidepressants may be beneficial in IBS. We report a case in which symptoms of diarrhea-predominan...
متن کاملTreatment of diarrhea-predominant irritable bowel syndrome with paroxetine.
Sir: Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder. The disorder is characterized by chronic abdominal pain and altered bowel habits in the absence of any organic disorder. Treatment of IBS includes dietary modification, psychotherapies, and medications. Among medications, antidepressants may be beneficial in IBS. We report a case in which symptoms of diarrhea-predominan...
متن کاملEluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
Eluxadoline is a novel drug approved for the management of diarrhea predominant irritable bowel syndrome (IBS-D). It has unique pharmacology and works on three different opioid receptors. Several Phase II and III clinical trials have demonstrated eluxadoline's efficacy in reducing symptoms related to IBS-D. Clinical trial results and postmarketing reports show a risk of pancreatitis in patients...
متن کاملTreatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine.
CONTEXT Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inflammation. Mesalazine has intestinal anti-inflammatory properties including cyclooxygenase and prostaglandin inhibition. The effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable b...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arquivos de Gastroenterologia
سال: 2013
ISSN: 0004-2803
DOI: 10.1590/s0004-28032013000400012